Table 2.

BRVO patients: demographics and baseline ocular characteristics

Parameter	Anti-VEGF n=105	Dex implant n=35	p value
Age (yrs±SD)	70.3±11.0	73.4±11.8	NS
BCVA (ETDRS letters±SD)	55.7±16.2	53.6±17.4	NS
CRT (μm±SD)	547±203	531±212	NS
Pseudophakia	22(20)	10 (29)	NS
Glaucoma/OHT n (%)	22 (21)	0 (0)	<0.01
Hypertension n (%)	61 (58)	19 (54)	NS
Diabetes mellitus n (%)	11 (10)	9 (26)	NS

VEGF vascular endothelial growth factor, Dex dexamethsone, BCVA best-corrected visual acuity, ETDRS Early Treatment Diabetic Retinopathy Study, CRT central retinal thickness, OHT ocular hypertension